Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies

Thrombosis and Haemostasis

Volumn 90, Issue 1, 2003, Pages 108-115

  Neville, Carolyn ^a   Rauch, Joyce ^a   Kassis, Jeannine ^b   Chang, Erika R ^c   Joseph, Lawrence ^a,d   Le Comte, Martine ^a   Fortin, Paul R ^c  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Anticadiolipin antibody; Antiphopholipid syndrome; Antiphospholipid antibodies; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; ESTROGEN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PREDNISONE; WARFARIN;

ADULT; AGE; ANAMNESIS; ANTIBODY DETECTION; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; BLOOD CELL COUNT; BLOOD SAMPLING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; FAMILY HISTORY; FEMALE; GENDER; HUMAN; HYPERTENSION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; TEACHING HOSPITAL; THROMBOEMBOLISM; THROMBOSIS; VEIN THROMBOSIS;

EID: 0038299178     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613606     Document Type: Article

References (40)

1. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 1999; 42: 1309-11.
2. Lockshin MD, Sammaritano LR, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum 2000; 43: 440-3.
3. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-63.
4. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 91-9.
5. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: An inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348:423-28.
6. Rauch J, Tannenbaum M, Neville C, Fortin PR. Inhibition of lupus anticoagulant activity by hexagonal phase phosphatidylethanolamine in the presence of prothrombin. Thromb Haemost 1998; 80: 936-41.
7. Price BE, Rauch J, Shia MA, et al. Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a beta 2-glycoprotein I-dependent manner. J Immunol 1996;157:2201-8.
8. SAS Institute Inc. The SAS System for Windows. (8.2). 2002. Cary, North Carolina, The SAS Institute.
9. El Roeiy A, Gleicher N. Definition of normal autoantibody levels in an apparently healthy population. Obstet Gynecol 1988; 72: 596-602.
10. Briley DP, Coull BM, Goodnight SH, Jr. Neurological disease associated with antiphospholipid antibodies. Ann Neurol 1989; 25: 221-7.
11. Fields RA, Toubbeh H, Searles RP, Bankhurst AD. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J Rheumatol 1989; 16: 623-5.
12. Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust N Z J Med 1990; 20: 231-6.
13. Phadke KV, Phillips RA, Clarke DT, Jones M, Naish P, Carson P. Anticardiolipin antibodies in ischaemic heart disease: Marker or myth? Br Heart J 1993; 69: 391-4.
14. Juby AG, Davis P. Prevalence and disease associations of certain autoantibodies in elderly patients. Clin Invest Med 1998; 21: 4-11.
15. Wu R, Nityanand S, Berglund L, Lithell H, Holm G, Lefvert AK. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 1997; 17: 3159-63.
16. Levine SR, Salowich-Palm L, et al. IgG anticardiolipin antibody tite > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 1997; 28: 1660-5.
17. Vaarala O, Manttari M, Manninen V, et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation 1995; 91: 23-7.
18. Glueck CJ, Lang JE, Tracy T, Sieve-Smith L, Wang P. Evidence that anticardiolipin antibodies are independent risk factors for atherosclerotic vascular disease. Am J Cardiol 1999; 83: 1490-4, A8.
19. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the Italian Registry. Am J Med 1996; 100: 530-6.
20. Zuckerman E, Toubi E, Shiran A, et al. Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythmatosus patients: A controlled prospective study. Am J Med 1996; 101: 381-6.
21. Kenet G, Sadetzki S, Murad H, et al. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 2000; 31: 1283-8.
22. Salomon O, Steinberg DM, Zivelin A, et al. Single and combined prothrombotic factors in patients with idiopathic venouos thromboembolism: Prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999; 19: 511-8.
23. Pablos JL, Caliz RA, Carreira PE, et al. Risk of thrombosis in patients with antiphospholipid antibodies and factor V Leiden mutation. J Rheumatol 1999; 26: 588-90.
24. Galli M, Finazzi G, Duca F, Norbis F, Moia M. The G1691 → A mutation of factor V, but not the G20210 → A mutation of factor II or the C677 → T mutation of methylenetetrahydrofolate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants. Br J Haematol 2000; 108: 865-70.
25. Nojima J, Suehisa E, Akita N, et al. Risk of arterial thrombosis in patients with anticardiolipin antibodies and lupus anticoagulant. Br J Haematol 1997; 96: 447-50.
26. Gattorno M, Buoncompagni A, Molinari AC, et al. Antiphospholipid antibodies in paediatric systemic lupus erythematosus, juvenile chronic arthritis and overlap syndromes: SLE patients with both lupus anticoagulant and high-titre anticardiolipin antibodie are at risk for clinical manifestations related to the antiphospholipid syndrome. Br J Rheumatol 1995; 34: 873-81.
27. Ginsberg JS, Wells PS, Brill-Edwards P, et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-91.
28. Horbach DA, Van Oort E, Donders RC, Derksen RH, De Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996; 76: 916-24.
29. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Neurology 1993; 43: 2069-73.
30. Wahl DG, De Maistre E, Guillemin F, Regnault V, Perret-Guillaume C, Lecompte T. Antibodies against phospholipids and beta 2-glycoprotein I increase the risk of recurrent venous thromboembolism in patients without systemic lupus erythematosus. QJM 1998; 91: 125-30.
31. Gomez-Pacheco L, Villa AR, Drenkard C, Cabiedes J, Cabral AR, Alarcon-Segovia D. Serum anti-beta2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients. Am J Med 1999; 106: 417-23.
32. McNally T, Mackie IJ, Machin SJ, Isenberg DA. Increased levels of beta 2 glycoprotein-I antigen and beta 2 glycoprotein-I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome. Br J Rheumatol 1995; 34: 1031-6.
33. Fiallo P, Tomasina C, Clapasson A, Cardo PP. Antibodies to beta(2)-glycoprotein I in ischemic stroke. Cerebrovasc Dis 2000; 10: 293-7.
34. Tsutsumi A, Matsuura E, Ichikawa K, Fujisaku A, Mukai M, Kobayashi S et al. Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996; 39: 1466-74.
35. Forastiero RR, Martinuzzo ME, Cerrato GS, Kordich LC, Carreras LO. Relationship of anti beta2-glycoprotein I and anti prothrombin antibodies to thrombosis and pregnancy loss in patients with antiphospholipid antibodies. Thromb Haemost 1997; 78: 1008-14.
36. Cucurull E, Espinoza LR, Mendez E, et al. Anticardiolipin and anti-beta2glycoprotein-I antibodies in patients with systemic lupus erythematosus: Comparison between Colombians and Spaniards. Lupus 1999; 8: 134-41.
37. Zanon E, Prandoni P, Vianello F, Saggiorato G, Carraro G, Bagatella P et al. Anti-beta2-glycoprotein I antibodies in patients with acute venous thromboembolism: Prevalence and association with recurrent thromboembolism. Thromb Res 1999; 96: 269-74.
38. Palosuo T, Virtamo J, Haukka J, et al. High antibody levels to prothrombin imply a risk of deep venous thrombosis and pulmonary embolism in middle-aged men - A nested case-control study. Thromb Haemost 1997; 78: 1178-82.
39. Vaarala O, Puurunen M, Manttari M, Manninen V, Aho K, Palosuo T. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost 1996; 75: 456-9.
40. Cuadrado MJ, Tinahones F, Camps MT, et al. Antiphospholipid, anti-beta 2-glycoprotein-I and anti-oxidized-low-density-lipoprotein antibodies in antiphospholipid syndrome. QJM 1998; 91: 619-26.